Compare BIO-TECHNE Corp (TECH) vs Vanguard Dividend Appreciation Index Fund ETF (VIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs Vanguard Dividend Appreciation Index Fund ETF — how do they compare? BIO-TECHNE Corp trades at $72.39 (market cap $11.34B), while Vanguard Dividend Appreciation Index Fund ETF trades at $239.07. The key difference: BIO-TECHNE Corp pays a 0.44% dividend while Vanguard Dividend Appreciation Index Fund ETF pays none, and BIO-TECHNE Corp is trading nearer its 52-week high, Vanguard Dividend Appreciation Index Fund ETF nearer its low. Which is the better fit depends on your goals.
| TECH | VIG | |
|---|---|---|
Market Cap | $11.34B | — |
Sector | Health | — |
52-Week High | $72.48 | $246.61 |
52-Week Low | $43.31 | $210.70 |
Enterprise Value | $11.36B | — |
Dividend Yield | 0.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $72.31, down 0.17% on the day, with a neutral technical signal and mixed earnings history. The stock is near the consensus price target of $71.86, with a pending acquisition by Merck KGaA at $73.00 per share. Recent Q4 2026 revenue beat estimates, but net income margin compression from 25.09% in 2023 to 14.96% in 2026 highlights profitability challenges. Operating cash flow remains stable around $290M, supporting dividend payments.
The outlook is balanced, with upside capped by the acquisition offer but supported by solid cash flow and analyst hold ratings. Risks include shareholder litigation and integration uncertainties post-acquisition. Earnings growth in diagnostics and spatial biology segments is a key catalyst, though high P/E of 62.33 suggests elevated expectations.
VIG trades at $240.11, down 0.79% with bearish technical signals from moving averages. The ETF maintains its dividend growth strategy, with a scheduled $1.00 dividend payment in June 2026. Recent news highlights institutional accumulation and comparisons with peer dividend ETFs, emphasizing VIG's defensive tech exposure and lower yield relative to competitors like SCHD.
Outlook remains cautious near-term due to technical pressure, but long-term dividend growth appeal persists for income-focused investors. Risks include interest rate sensitivity and yield competition, while institutional buying signals underlying confidence in the strategy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About Vanguard Dividend Appreciation Index Fund ETF
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that have a record of increasing dividends over time. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VIG →
